

## LISTING OF CLAIMS

This listing of the claims replaces all prior versions and listings of claims in the application:

- Claim 1 (Currently Amended) A method for inhibiting HLA alloimmune response to platelet transfusion, said method comprising the step of presensitizing platelets with at least one monoclonal antibody against HLA Class I, an F(ab')<sub>2</sub> ~~an antigen-binding~~ fragment thereof or  $\beta$ 2-microglobulin, wherein said platelets if administered to a patient prevent an HLA alloimmune response in patient.
- Claim 2 (Cancelled)
- Claim 3 (Currently Amended) A method for inhibiting an HLA alloimmune response to platelet transfusion, said method comprising the steps of:
- a) presensitizing platelets with at least one monoclonal antibody against HLA Class I, an F(ab')<sub>2</sub> ~~an antigen-binding~~ fragment thereof or  $\beta$ 2-microglobulin;
  - b) transfusing the presensitized platelets of step a) into a patient, said presensitized platelets inhibiting an HLA alloimmune response in said patient.
- Claim 4 (Previously Amended) The method of claim 3, wherein said HLA alloimmune response is still inhibited after at least two transfusions into said patient.
- Claim 5 (Currently Amended) in an alloimmunized patient, comprising the steps of:
- a) presensitizing platelets with at least one monoclonal antibody against HLA Class I, an F(ab')<sub>2</sub> ~~an antigen-binding~~ fragment thereof or  $\beta$ 2-microglobulin; and
  - b) transfusing the alloimmunized patient with the presensitized platelets of step a), the presensitized platelets preventing refractoriness to the transfusion.